SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
Open Access
- 21 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-7
- https://doi.org/10.1038/s41598-021-81629-2
Abstract
In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points. Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p = 0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had NAbs, 38/76 (50%) in those with > 90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness.Keywords
Other Versions
Funding Information
- Centre for Dengue Research
- Medical Research Council, UK
- Singapore National Medical Research Council (STPRG-FY19-001)
- Foreign and Commonwealth Office, UK
This publication has 29 references indexed in Scilit:
- Convalescent plasma transfusion for the treatment of COVID-19: Systematic reviewJournal of Medical Virology, 2020
- Phenotype and functionality of follicular helper T cells in patients with acute dengue infectionJournal of Biomedical Science, 2020
- Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal KenyaThe Journal of Infectious Diseases, 2018
- MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015Emerging Infectious Diseases, 2017
- Persistence of Antibodies against Middle East Respiratory Syndrome CoronavirusEmerging Infectious Diseases, 2016
- Homotypic Dengue Virus Reinfections in Nicaraguan ChildrenThe Journal of Infectious Diseases, 2016
- Disappearance of Antibodies to SARS-Associated Coronavirus after RecoveryThe New England Journal of Medicine, 2007
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Initial viral load and the outcomes of SARSCMAJ : Canadian Medical Association Journal, 2004
- Viral Loads in Clinical Specimens and SARS ManifestationsEmerging Infectious Diseases, 2004